Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44 Page 45 Page 46 Page 47 Page 48 Page 49 Page 50 Page 51 Page 52 Page 53 Page 54 Page 55 Page 56 Page 57 Page 58 Page 59 Page 60 Page 61 Page 62 Page 63 Page 64 Page 65 Page 66 Page 67 Page 68THE 7:16 WAS ON TIME BUT MY LEGS WERE BEHIND SCHEDULE THE WALKING PILL THAT’S WHEN I ASKED FOR Today is the day to ask your doctor about a FREE* 60-day trial. start AMPYRA. AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same. AMPYRA may cause serious side effects, including đƫƫ /!2!.!ƫ ((!.#% ƫ.! 0%+*/ċƫ0+,ƫ0 '%*#ƫ ƫ * ƫ ((ƫ5+1.ƫ doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives; đƫ'% *!5ƫ+.ƫ ( !.ƫ%*"! 0%+*/ċ $!ƫ)+/0ƫ +))+*ƫ 2!./!ƫ!2!*0/ƫ"+.ƫ ƫ%*ƫ ƫ, 0%!*0/ƫ were urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, problems with balance, multiple sclerosis relapse, burning, tingling, or itching of your skin, irritation in your nose and throat, constipation, indigestion, and pain in your throat. For additional safety information, please see the Patient Medication Guide on the following page. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. IMPORTANT SAFETY INFORMATION continued... IMPORTANT SAFETY INFORMATION Do not take AMPYRA if you đƫ$ 2!ƫ!2!.ƫ$ ƫ ƫ/!%61.!Č đƫ$ 2!ƫ !.0 %*ƫ05,!/ƫ+"ƫ'% *!5ƫ,.+ (!)/Čƫ+. đƫƫ .!ƫ ((!.#% ƫ0+ƫ (" ),.% %*!ƫĨąġ )%*+,5.% %*!ĩČƫ0$!ƫ 0%2!ƫ ingredient in AMPYRA. Take AMPYRA exactly as prescribed by your doctor. Before taking AMPYRA, tell your doctor if you đƫ$ 2!ƫ'% *!5ƫ,.+ (!)/ƫ+.ƫ *5ƫ+0$!.ƫ)! % (ƫ +* %0%+*/ đƫ .!ƫ0 '%*#ƫ +),+1* ! ƫąġ )%*+,5.% %*! đƫƫ .!ƫ,.!#* *0ƫ+.ƫ,( *ƫ0+ƫ ! +)!ƫ,.!#* *0ċƫ 0ƫ%/ƫ*+0ƫ'*+3*ƫ if AMPYRA will harm your unborn baby. đƫƫ .!ƫ .! /0ġ"!! %*#ƫ+.ƫ,( *ƫ0+ƫ .! /0ġ"!! ċƫ 0ƫ%/ƫ*+0ƫ'*+3*ƫ%"ƫ AMPYRA passes into your breast milk. You and your doctor should decide if you will take AMPYRA or breast-feed. You should not do both. đƫ .!ƫ0 '%*#ƫ *5ƫ+0$!.ƫ)! % %*!/ 0+,ƫ0 '%*#ƫ ƫ * ƫ ((ƫ5+1.ƫ + 0+.ƫ.%#$0ƫ 3 5ƫ%"ƫ5+1ƫ have a seizure while taking AMPYRA. You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50. Your doctor may do a blood test to check how well your kidneys are working before you AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, is the only product indicated to help improve walking in adults with MS. This was demonstrated by an increase in walking speed. AMPYRA does not work for everyone, and people experience different levels of response to the medication. Ask your doctor if AMPYRA may be right for you. Actor portrayal TO FIND OUT MORE ABOUT A FREE* TRIAL, VISIT AMPYRAFREETRIAL.COM *Limitations and restrictions apply. AMPYRA®Čƫƫ ®ƫ * ƫ0$!ƫ/05(%6! ƫƫ ®ƫ(+#+ƫ .!ƫ.!#%/0!.! ƫ0. !) .'/ƫ+"ƫ +. ƫ$!. ,!10% /Čƫ * ċƫħƫ ® is marketed by Acorda $!. ,!10% /Čƫ * ċƫ * ƫ) *1" 01.! ƫ1* !.ƫ(% !*/!ƫ".+)ƫ('!.)!/ƫ$ .) ƫ .!( * ƫ %)%0! ƫĨ ĩČƫ .!( * ċƫħƫ$!ƫ/05(%6! ƫ, 0$ƫ(+#+ƫ * ƫ0$!ƫ/05(%6! ƫ +. ƫ(+#+ƫ .!ƫ 0. !) .'/ƫ+"ƫ +. ƫ$!. ,!10% /Čƫ * ċƫħƫįƫĂĀāĆƫ +. ƫ$!. ,!10% /Čƫ * ċƫ((ƫ.%#$0/ƫ.!/!.2! ċƫĀăĥāĆƫ ăąćĆ